Sentinel node biopsy in the management of malignant melanoma

Clinical and Experimental Dermatology

Volumn 26, Issue 6, 2001, Pages 463-468

  Russell Jones, R ^a   Acland, K ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; GANGLIOSIDE GM2; INTERFERON;

ADJUVANT CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; ELECTROCORTICOGRAPHY; HUMAN; LYMPH NODE DISSECTION; MELANOMA; METASTASIS; PRIORITY JOURNAL; REVIEW; SENTINEL LYMPH NODE BIOPSY; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

HUMANS; IMMUNOHISTOCHEMISTRY; MELANOMA; NEOPLASM STAGING; S100 PROTEINS; SENTINEL LYMPH NODE BIOPSY; SKIN NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0034791883     PISSN: 03076938     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2230.2001.00868.x     Document Type: Review

References (27)

1. Technical details of intraoperative mapping for early stage melanoma
2. Efficacy of an elective regional lymph node dissection of 1-4 mm thick melanomas for patients 60 years of age and younger
3. Immediate or delayed dissection of regional nodes in patients with melanoma of the trunk: A randomised trial
4. Multi-institutional melanoma lymphatic mapping experience: The prognostic value of sentinel node status in 612 stage i or ii melanoma patients
5. Comparison of PET scanning and sentinel node biopsy in the detection of micrometastases of primary cutaneous malignant melanoma
6. S100 levels are not useful in predicting micrometastatic disease in malignant melanoma
7. Molecular staging of malignant melanoma
8. Examination of regional lymph nodes by sentinel node biopsy and molecular analysis provides new staging facilities in primary cutaneous melanoma
9. A new American Joint Committee on Cancer Staging System for Cutaneous Melanoma
10. The argument against sentinel node biopsy for malignant melanoma
11. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group Trial EST 1684
12. High and low-dose Interferon alfa-2b in high-risk melanoma: First analysis of intergroup trial E 1690/S 9111/c 9190
13. Relapse-free and overall survival are significantly prolonged by high-dose 1FN-alpha 2b (HD1) compared to vaccine GM2-KLH with QS21 (GMK Progenics) for high-risk resected Stage 11B-111 melanoma: Results of the Intergroup Phase III study E1694/S9512/C503, 801
14. Improved survival in Stage III melanoma patients with GM2 ganglioside
15. Sentinel lymph node biopsy for melanoma. Experience with 234 consecutive procedures
16. Towards quality assurance of the sentinel node procedure in malignant melanoma patients: A single institution evaluation and a european survey
17. The progression of melanoma nodal metastases is dependent on tumour thickness of the primary lesion
18. Surgical management of occult lymph node metastases
19. Functional alterations in dendritic cell activities from the sentinel lymph nodes in cutaneous melanoma
20. Patterns of failure in patients with thick (>4 mm) melanoma undergoing sentinel node biopsy
21. Long-term results of a multi-institutional randomised trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0-4.0 mm)
22. Reliability of sentinel lymph node biopsy for staging melanoma
23. Sentinel lymph node biopsy in malignant melanoma: A series of 100 consecutive patients
24. Intraoperative radio lymphoscintigraphy improves sentinel node identification for patients with melanoma
25. The impact of dynamic lymphoscintigraphy and gamma probe guidance on sentinel node biopsy in melanoma
26. Gamma probe-guided sentinel node biopsy to select patients with melanoma for lymphadenectomy
27. WHO declares lymphatic mapping to be the standard of care for melanoma